Your browser doesn't support javascript.
loading
Human skeletal myopathy myosin mutations disrupt myosin head sequestration.
Carrington, Glenn; Hau, Abbi; Kosta, Sarah; Dugdale, Hannah F; Muntoni, Francesco; D'Amico, Adele; Van den Bergh, Peter; Romero, Norma B; Malfatti, Edoardo; Vilchez, Juan Jesus; Oldfors, Anders; Pajusalu, Sander; Õunap, Katrin; Giralt-Pujol, Marta; Zanoteli, Edmar; Campbell, Kenneth S; Iwamoto, Hiroyuki; Peckham, Michelle; Ochala, Julien.
Afiliação
  • Carrington G; The Astbury Centre for Structural and Molecular Biology and.
  • Hau A; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
  • Kosta S; Centre of Human and Applied Physiological Sciences and.
  • Dugdale HF; Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, United Kingdom.
  • Muntoni F; Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
  • D'Amico A; Centre of Human and Applied Physiological Sciences and.
  • Van den Bergh P; School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.
  • Romero NB; UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Malfatti E; NIHR Biomedical Research Centre at Great Ormond Street Hospital, Great Ormond Street, London, United Kingdom.
  • Vilchez JJ; Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Oldfors A; Neuromuscular Reference Center, Neurology Department, University Hospital Saint-Luc, Brussels, Belgium.
  • Pajusalu S; Neuromuscular Morphology Unit, Institute of Myology, Myology Research Centre INSERM, Sorbonne University, Hôpital Pitié-Salpêtrière, Paris, France.
  • Õunap K; APHP, Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France, Henri Mondor Hospital, Inserm U955, Creteil, France.
  • Giralt-Pujol M; U1179 UVSQ-INSERM Handicap Neuromuscular: Physiology, Biotherapy and Applied Pharmacology, UFR Simone Veil-Santé, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.
  • Zanoteli E; Neuromuscular and Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
  • Campbell KS; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Spain, Valencia, Spain.
  • Iwamoto H; Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Peckham M; Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia.
  • Ochala J; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
JCI Insight ; 8(21)2023 Nov 08.
Article em En | MEDLINE | ID: mdl-37788100
Myosin heavy chains encoded by MYH7 and MYH2 are abundant in human skeletal muscle and important for muscle contraction. However, it is unclear how mutations in these genes disrupt myosin structure and function leading to skeletal muscle myopathies termed myosinopathies. Here, we used multiple approaches to analyze the effects of common MYH7 and MYH2 mutations in the light meromyosin (LMM) region of myosin. Analyses of expressed and purified MYH7 and MYH2 LMM mutant proteins combined with in silico modeling showed that myosin coiled coil structure and packing of filaments in vitro are commonly disrupted. Using muscle biopsies from patients and fluorescent ATP analog chase protocols to estimate the proportion of myosin heads that were super-relaxed, together with x-ray diffraction measurements to estimate myosin head order, we found that basal myosin ATP consumption was increased and the myosin super-relaxed state was decreased in vivo. In addition, myofiber mechanics experiments to investigate contractile function showed that myofiber contractility was not affected. These findings indicate that the structural remodeling associated with LMM mutations induces a pathogenic state in which formation of shutdown heads is impaired, thus increasing myosin head ATP demand in the filaments, rather than affecting contractility. These key findings will help design future therapies for myosinopathies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Musculares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Musculares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article